

employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.

PATHWAY PRIMER

- This pathway has been developed in part to ensure **early diagnosis of patients at high risk of colon cancer or other GI cancers**, which present with iron deficiency, such as gastric and esophageal cancer.
- It is recognized there are several other causes of iron deficiency anemia.
- It is important that iron deficiency is appropriately investigated and in a timely manner.
- GI Causes of Iron Deficiency Anemia
 - o Iron Deficiency Anemia (IDA) has many causes but this pathway focuses on GI causes of IDA
 - Common causes of IDA without obvious evidence of GI tract bleeding (blood in stool, melena) include:
 - heavy menstruation in women
 - It is important to know in women whether they are still menstruating or whether they have had a hysterectomy
 - colon cancer
 - other GI tract cancers, including esophageal and gastric cancer
 - peptic ulcer disease
 - celiac disease
 - inflammatory bowel disease (IBD)
 - chronic GI blood loss from small vascular or mucosal lesions, often associated with use of anti-platelet agents, NSAIDS and anti-coagulants
 - chronic GI blood loss due to other causes
 - poor iron intake
 - Poor iron intake is a rare cause of significant iron deficiency. It is generally advisable that patients are investigated for other cause of iron deficiency.
- Celiac disease i causes IDA because of impaired absorption of iron not because of excess GI tract blood loss. Testing for celiac disease, by the TTG blood test (anti-transglutaminase anti body), is important in the work-up of IDA. It is no longer required to also order an IgA level when ordering TTG.

• Definition of Iron Deficiency Anemia

- For diagnosis of IDA, *both* the Hemoglobin (Hb) and iron *must be low*.
- Anemia is present when Hb is <130 g/L in men and <120 g/L in women.
- Arbitrarily the following criteria have been set
 - URGENT
 - IDA with >30 g/L drop in Hb (Hb drop can occur over a long time period and requires clinical judgement to assess) OR
 - IDA with Hb has dropped to <100 g/L
 - IDA with alarm symptom concerning for colorectal or other GI cancer:
 - Significant diarrhea, as can occur in IBD
 - Unintentional weight loss (\geq 5-10% of body weight over 6 months)
 - Significant and progressive change in bowel habit
 - Significant abdominal pain
 - SEMI-URGENT
 - IDA with <30 g/L drop in Hb (Hb drop can occur over a long time period and requires clinical judgement to assess) OR
 - IDA with Hb >100 g/L
- Serum ferritin is the best test for diagnosis of iron deficiency.
 - Iron deficiency is defined as serum ferritin <45 ug/L.
 - Ferritin is more accurate than serum iron or TIBC (total iron binding capacity) and transferrin saturation.
 - A transferrin saturation <16% supports the diagnosis of IDA.

- The *caveat* of a serum ferritin is that it is an acute phase reactant, meaning that it is elevated when active inflammation, such as can be seen in IBD, is present.
- In individuals with active inflammation (ongoing infection or active IBD) a ferritin <100 ug/mL supports the diagnosis of iron deficiency.

The Iron Primer listed below further explains the diagnosis of iron deficiency.

Iron Primer

Evaluation of measures of iron storage can be challenging. Gastrointestinal (occult) blood loss is a common cause of iron deficiency and should be considered as a cause when iron deficiency anemia is present.

- Two main serological tests best evaluate iron stores (ferritin, transferrin saturation) neither of which are perfect.
- The first step is to evaluate a **serum ferritin**:
 - o If the serum ferritin is low, it is diagnostic of iron deficiency, with high specificity (98% specificity).
 - Ferritin is an acute phase reactant, which may be elevated in the context of acute inflammation and infection. If you suspect this to be the case, order a transferrin saturation (see below).
 - However, if the ferritin is above 100 ug/L and there is no concurrent significant chronic renal insufficiency, iron deficiency is very unlikely – even in the context of acute inflammation/infection.
- The second step is to evaluate transferrin saturation:
 - The transferrin saturation is a calculated ratio using serum iron and total iron binding capacity. Serum iron alone does **not** reflect iron stores.
 - Low values (less than 10%) demonstrate low iron stores in conjunction with a ferritin <100 ug/L.
- In the absence of abnormal iron indices, anemia may be from other causes other than (occult) blood loss (e.g., bone marrow sources, menstruation).

EXPANDED DETAILS

This pathway focuses on IDA as the main presentation.

1. Signs of IDA

- For diagnosis of IDA, *both* the Hemoglobin (Hb) and iron *must be low*.
- Anemia is present when Hb is <130 g/L in men and <120 g/L in women.
- Serum ferritin is the best test for diagnosis iron deficiency.
 - *Iron deficiency* is defined as serum ferritin <45 ug/L.
 - Ferritin is more accurate than serum iron or TIBC (total iron binding capacity) and transferrin saturation.
 - A transferrin saturation <16% supports the diagnosis IDA.
 - The *caveat* of a serum ferritin is that it is an acute phase reactant, meaning that it is elevated when active inflammation, such as can be seen in IBD, is present.
 - In individuals with active inflammation (ongoing infection or active IBD) a ferritin <100 ug/mL supports diagnosis of iron deficiency.

2. a. Rule out celiac disease

- It is important a TTG blood test to rule out celiac disease is ordered.
- This is not required if it was done in the past (<5 years) or the patient previously had a normal duodenal endoscopic biopsy (taken during gastroscopy).
- It is no longer required to also order an IgA level when ordering TTG
- Although celiac disease is often associated with other GI symptoms, iron deficiency anemia can be its only manifestation.

2. b. Address gynecology causes

• It is important to know in women whether they are still menstruating or whether they have had a hysterectomy

3. Is there high risk rectal bleeding?

- Rectal bleeding (blood visibly present in stool or in the toilet and not just on the tissue paper) is defined as high risk if it is new onset or worsening and persistent (not a single episode, present most days of the week for more than 2 weeks).
 - The incidence colorectal cancer has been rising among patients less than age 50, but the absolute risk remains low. Adult patients of all ages can have high risk rectal bleeding, but the bleeding must be accompanied by the presence of other alarm features to be suitable for this pathway.
- Follow the high risk rectal bleeding pathway for colorectal cancer diagnosis (can be found on Specialist Link and Connect MD) if high risk rectal bleeding is present.

4. Medication review

- New medications may be implicated, especially anti-platelet agents and/or anti-coagulants.
- Use of anti-coagulation or anti-platelet agents increases the risk of bleeding, but, if present, it still means the
 patient needs to be investigated for the cause

5. Baseline investigations

- Baseline investigations to identify concerning features or clear etiologies must include:
 - CBC, ferritin, SeFe, TIBC and Transferrin saturation
 - TTG (not required if done in the past 5 yeras)

Recommended blood tests:

- Creatinine, ALT, Alkaline Phosphatase, bilirubin, LFTs
- CRP, especially if there is possibility of inflammatory cause, such as ulcerative colitis or Crohns disease

6. Physical exam

• Consider rectal exam, especially if there is also a change in bowel habit or lower abdominal pain

7. Consider alarm symptoms concerning colorectal or other GI cancer

- *Alarm symptoms*, when present, are important to consider and will determine urgency of referral for endoscopic evaluation. IDA with include:
 - Significant diarrhea, as can occur in IBD
 - Unintentional weight loss (≥5-10% of body weight over 6 months)
 - Significant and progressive change in bowel habit
 - Significant abdominal pain
- Other features, when present, are important to consider and may influence triage of the referral for endoscopic evaluations. These include:
 - IDA onset age >40
 - Family history of inflammatory bowel disease (IBD) or colorectal cancer (first-degree relative)
 - Evidence of GI bleeding

- Nocturnal symptoms
- 8. Urgent criteria for IDA pathway for colorectal cancer diagnosis
 - If there is IDA with:
 - o >30 g/L drop in hemoglobin OR
 - Hb has dropped to <100 g/L OR
 - \circ $\;$ With alarm symptom concerning for colorectal or other GI cancer including
 - Significant diarrhea, as can occur in IBD
 - Unintentional weight loss (≥ 5-10% of body weight over 6 months)
 - Significant and progressive change in bowel habit
 - Significant abdominal pain

The referral is urgent meaning the patient should be evaluated (gastroscopy and colonoscopy) in ≤ 2 weeks.

- Certain group of patients such as those with chronic advanced kidney disease or elderly individuals with anemia of chronic disease may have baseline Hb levels below the normal range (i.e., Hb is <130 g/L in men and <120 g/L in women).
- A significant unexplained drop in Hb from their baseline is a reason for referral for endoscopy.
- Referral content requirements:
 - If > 30 g/L drop in Hb: urgent
 - Information over period in which Hb drop occurred:
 - Hb
 - Ferritin
 - SeFe, TIBC, and Transferrin saturation
 - TTG
 - Creatinine
 - ALT, Alkaline Phosphatase, Bilirubin
 - CRP (if there is possibility of inflammatory cause)
 - o Medications: especially anti-platelet agents and/or anti-coagulants
 - Physical exam: describe findings of rectal exam if completed, especially if there is also a change in bowel habit or lower abdominal pain

9. Semi-urgent criteria for IDA pathway for colorectal cancer diagnosis

- If there is IDA with <30 g/L drop in Hb AND/OR Hb > 100g/L the patient should be evaluated (gastroscopy and colonoscopy) in <8 weeks.
- Referral content requirements:
 - If IDA with < 30 g/L drop in Hb AND/OR Hb >100g/L: semi-urgent
 - Information over period in which Hb drop occurred:
 - Hb
 - Ferritin
 - SeFe, TIBC, and Transferrin saturation
 - TTG
 - Creatinine
 - ALT, Alkaline Phosphatase, Bilirubin
 - CRP (if there is possibility of inflammatory cause)

- Medications: especially anti-platelet agents and/or anti-coagulants
- Physical exam: describe findings of rectal exam if completed, especially if there is also a change in bowel habit or lower abdominal pain



 \bigcirc

BACKGROUND

About this Pathway

- The creation of the Colorectal Cancer Diagnosis Pathway builds on the success of previous pathways
 including lung, breast and prostate cancer. Building out multiple cancer diagnosis pathways has begun to
 create end-to-end pathways for cancer patients in Alberta on a provincial scale with the goals of expedited
 cancer diagnosis and providing better support to patients through that process.
- Initial work on this pathway was started in May 2019 and is being implemented over two years. Patients, providers and administrators from relevant areas were brought together to gather information on current experiences with colorectal diagnosis, collect data on how the system is performing and review best practice evidence. Provincial principles of care, strategic areas for improvement in Alberta and a provincial measurement and reporting framework were defined.
- Primary Care providers were engaged to co-design pathways with patients, gastroenterologists, colorectal surgeons and GI intake programs.
- Local implementation teams will be engaged in work around planning and pathway roll-out, determination of barriers and facilitators, and shared learnings with other sites. Performance dashboard reports will be developed and disseminated to provide feedback to clinical teams on pathway performance and outcomes. Sustainability planning will be initiated early with implementation teams to ensure successful transition of pathways to operations at the end of the initiative.

Authors & Conflict of Interest Declaration

This pathway was reviewed and revised under the auspices of the Cancer Strategic Clinical Network (CSCN) in 2020 by a multi-disciplinary team led by family physicians, gastroenterologists and colorectal surgeons. For more information, contact the CSCN at <u>Cancer.SCN@ahs.ca</u>.

Pathway Review Process

Specialty access pathways undergo scheduled review every three years, or earlier, if there is a clinically significant change in knowledge or practice. The next scheduled review is June 2023. However, we welcome feedback at any time. Please email comments to <u>Cancer.SCN@ahs.ca</u>.

Copyright Information



This work is licensed under a Creative Commons Attribution-Non-commercial-Share Alike 4.0 International license. You are free to copy, distribute, and adapt the work for non-commercial purposes, as long as you attribute the work to Alberta Health Services and Primary Care Networks and abide by the other license terms. If you alter, transform, or build upon this work, you may distribute the resulting work only under the same, similar, or compatible license. The license does not apply to content for which the Alberta Health Services is not the copyright owner.

Disclaimer

This pathway represents evidence-based best practice, but does not override the individual responsibility of health care professionals to make decisions appropriate to their patients using their own clinical judgment given their patients' specific clinical conditions, in consultation with patients/alternate decision makers. The pathway is not a substitute for clinical judgment or advice of a qualified health care professional. It is expected that all users will seek advice of other appropriately qualified and regulated health care providers with any issues transcending their specific knowledge, scope of regulated practice or professional competence.

PROVIDER RESOURCES

Advice Options

Non-urgent advice is available to support family physicians.

- Gastroenterology advice is available across the province via Alberta Netcare eReferral Advice Request (responses are received within five calendar days). Visit <u>www.albertanetcare.ca/documents/Getting-Started-Advice-Requests-FAQs.pdf</u> for more information.
- Non-urgent telephone advice connects family physicians and specialists in real time via a tele-advice line. Family physicians can request non-urgent advice from a gastroenterologist:
 - In the Calgary Zone at <u>specialistlink.ca</u> or by calling 403-910-2551. This service is available from 8:00 a.m. to 5:00 p.m., Monday to Friday (excluding statutory holidays). Calls are returned within one hour.
 - In the Edmonton and Zones by calling 1-844-633-2263 or visiting <u>www.pcnconnectmd.com</u>. This service is available from 9:00 a.m. to 6:00 p.m., Monday to Thursday and 9:00 a.m. to 4:00 p.m., Friday (excluding statutory holidays and Christmas break). Calls are returned within two business days.

PATIENT RESOURCES

Information

| Description | Website |
|---|--|
| Iron Deficiency Anemia Care Instructions | https://myhealth.alberta.ca/Health/aftercareinformation/pages/conditions.aspx?hwid=uf838 |
| Anemia Care Instructions | https://myhealth.alberta.ca/Health/aftercareinformation/pages/conditions.aspx?hwid=uf814 Z |
| Iron Test | https://myhealth.alberta.ca/Health/pages/conditions.aspx?hwid=hw41550& |
| Celiac Disease Care Instructions | https://myhealth.alberta.ca/Health/aftercareinformation/pages/conditions.aspx?hwid=abp79 38 |

Services Available

| Description | Website |
|-------------|---------|
| | |
| | |

 \bigcirc